Poster
Pipeline Compounds
ESMO 2026 | October 23 - 27, 2026
A first-in-human phase 1 dose-escalation study of DS-1471 in patients with advanced/metastatic solid tumors
This site is for U.S. Healthcare Professionals only.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Poster
T-DXd
ASCO 2026 | May 29 - June 2, 2026
A pragmatic, hybrid observational study evaluating the effectiveness of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 immunohistochemistry 3+ solid tumors: DESTINY-PanTumor04
Mini-Oral
Pipeline Compounds
JSMO 2026 | March 26-28, 2026
DS-3939, a TA-MUC1 antibody–drug conjugate in advanced/metastatic solid tumors: Initial first-in-human results
Poster
T-DXd
ESMO 2026 | October 23 - 27, 2026
ESPERANZA: Results from an external comparator study of trastuzumab deruxtecan in HER2 IHC3+ solid tumors
Oral
HER3-DXd
JSMO 2026 | March 26-28, 2026
HERTHENA-PanTumor01: Expansion of a global phase 2 trial of HER3-DXd in patients with advanced/metastatic solid tumors
Poster
T-DXd
ESMO 2026 | October 23 - 27, 2026
Human epidermal growth factor receptor 2 expression across multiple solid tumor types: Insights from the ESPERANZA program
Mini-Oral
HER3-DXd
ESMO 2026 | October 23 - 27, 2026
Patritumab deruxtecan (HER3-DXd) in melanoma after anti–PD-(L)1 therapy: Primary analysis from HERTHENA-PanTumor01
Poster
Other/Multi
ACoP16 | October 18-21, 2025
QSP I-O & ADCs: Integration of an antibody-drug conjugates mechanistic model into an immuno‐oncology quantitative systems pharmacology platform
Poster
T-DXd
ASCO 2026 | May 29 - June 2, 2026
Trastuzumab deruxtecan for pretreated patients in China with HER2 IHC 3+ solid tumors: DESTINY-PanTumor03 part 1 primary analysis
Poster
T-DXd
ESMO 2025 | October 17-21, 2025
Trastuzumab deruxtecan for pretreated patients with HER2-expressing solid tumors: DESTINY-PanTumor02 part 1 final analysis
Pages:
1 2